Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
Topical delgocitinib improved eczema severity scores and caused fewer adverse events than oral alitretinoin in adults with severe chronic hand eczema, according to a phase 3 study.
The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.
“It’s a way to practice self-preservation in this field that is punishing patients and doctors alike” — one internist explains why some rural physicians are opting for concierge care despite the access trade-offs.